Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Daniel S. Pilch
Rbhs Robert Wood Johnson Medical School, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
TAXIS Pharmaceuticals, Inc.
Other : Advisory Board and Co-Founder
One of the projects that Taxis is working on in house overlaps with this study, and involves designing drugs that interfere with FtsZ, a protein essential for bacterial cell division. The drugs most often discussed by the company are TXA 709 and TXA 707. Both are considered to be the precursor molecules for the current study which is focused upon TXY541 and PC190723. However, Dr. Pilch has published on both TXY541 and on TXA 709. Hence, the perception of a COI is fairly clear.
Development of New Antibiotics Against Multidrug-Resistant Staphylococcus aureus
Project Narrative Antibacterial resistance is an increasingly serious threat to global public health. In recognition of this threat, the President?s Council of Advisors on Science and Technology (PCAST) has recently submitted a report to President Obama underscoring the urgency for the development of new antibiotics. The proposed project will develop new antibiotics that act against a novel bacterial target. Ultimately, the results of the proposed work will enable us to take a major step toward addressing the urgent need for new drugs to treat multidrug-resistant bacterial infections that will be effective even when current drugs fail.
Filed on July 08, 2016.
Tell us what you know about Daniel S. Pilch's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Daniel S. Pilch filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Daniel S. Pilch | Rbhs Robert Wood Johnson Medical School | Conflict of Interest | TAXIS Pharmaceuticals, Inc. | >$600,000 |
| Daniel S. Pilch | Rbhs Robert Wood Johnson Medical School | Conflict of Interest | TAXIS Pharmaceuticals, Inc. | $0 - $4,999 |
| Daniel S. Pilch | Rbhs Robert Wood Johnson Medical School | Conflict of Interest | TAXIS Pharmaceuticals, Inc. | $0 - $4,999 |
| Daniel S. Pilch | Rbhs Robert Wood Johnson Medical School | Conflict of Interest | TAXIS Pharmaceuticals, Inc. | $0 - $4,999 |
| Daniel S. Pilch | Rbhs Robert Wood Johnson Medical School | Conflict of Interest | TAXIS Pharmaceuticals, Inc. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.